BiotechTube
Sporos Biodiscovery

Sporos Biodiscovery

San Diego, United States· Est.
sporosbiodiscovery.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.5M

Overview

Sporos Biodiscovery is a private, preclinical biotech founded in 2021 and based in San Diego. The company is advancing a pipeline of small molecules targeting tumor-intrinsic pathways and the immunosuppressive tumor microenvironment, with its most advanced candidate, SPR1 (a TEAD1/4 inhibitor), in IND-enabling studies. Sporos leverages a genetically-validated framework and a team of seasoned drug developers and cancer biologists to build its portfolio, aiming to overcome resistance to existing therapies like MAPK inhibitors and immuno-oncology agents.

Oncology

Technology Platform

Genetically-validated framework for target discovery, integrating bioinformatic analysis and cancer biology to identify tumor-specific vulnerabilities and co-dependencies within the tumor microenvironment.

Funding History

1
Total raised:$3.5M
Seed$3.5M

Opportunities

The lead TEAD inhibitor program addresses a novel, genetically-defined oncology target with potential in both monotherapy and combination to overcome resistance to MAPK inhibitors.
The TME-focused pipeline aims to convert immunologically 'cold' tumors, potentially expanding the reach of the large immuno-oncology market.

Risk Factors

High preclinical failure risk for all novel mechanisms.
Heavy reliance on venture funding and a consultant-based operational model creates financial and execution risk.
The TEAD inhibitor space is becoming increasingly competitive.

Competitive Landscape

The TEAD inhibitor field includes clinical-stage players like Vivace Therapeutics and Ikena Oncology, and preclinical competitors. The TME chemokine receptor space (CXCR2/CCR2) has seen mixed clinical results, with several prior candidates failing to show efficacy, representing a significant translational challenge.

More companies in Small Molecule Drugs →More companies in United States →